Insmed
INSM
Market cap $12.9B

98.73 USD

+1.85

1.91%

At close Jun 13, 4:00 PM EDT

After hours

98.26

-0.47

0.48%

1 day

1.91%

5 days

33.47%

1 month

50.25%

3 months

31.52%

6 months

37.83%

Year to date

41.14%

1 year

60.20%

5 years

247.76%

10 years

328.89%

About: Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

Employees: 1,271

Healthcare Biotechnology

0

Funds holding %

of 7,296 funds

0

Analysts bullish %

of 10 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

23% more repeat investments, than reductions

Existing positions increased: 183 | Existing positions reduced: 149

14% more capital invested

Capital invested by funds: $13.3B [Q4 2024] → $15.2B (+$1.87B) [Q1 2025]

12% more first-time investments, than exits

New positions opened: 55 | Existing positions closed: 49

7% more funds holding in top 10

Funds holding in top 10: 29 [Q4 2024] → 31 (+2) [Q1 2025]

1.67% more ownership

Funds ownership: 107.61% [Q4 2024] → 109.28% (+1.67%) [Q1 2025]

0% less funds holding

Funds holding: 434 [Q4 2024] → 433 (-1) [Q1 2025]

50% less call options, than puts

Call options by funds: $73M | Put options by funds: $145M

See Fund Rankings

Research analyst outlook

10 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$102

3%

upside

Avg. target

$111

12%

upside

High target

$120

22%

upside

10 analyst ratings

10 positive

100%

0 neutral

0%

0 negative

0%

Goldman Sachs Andrea Tan	13%upside $112	Buy Maintained	11 Jun 2025
Mizuho Graig Suvannavejh	11%upside $110	Outperform Maintained	11 Jun 2025
RBC Capital Leonid Timashev	7%upside $106	Outperform Maintained	11 Jun 2025
Morgan Stanley Matthew Harrison	3%upside $102	Overweight Maintained	11 Jun 2025
B of A Securities Jason Zemansky	10%upside $109	Buy Maintained	11 Jun 2025

See Analyst Rankings

Financial journalist opinion

Based on 14 articles about INSM published over the past 30 days

Insmed Announces Pricing of $750 Million Public Offering of Common Stock

BRIDGEWATER, N.J. , June 11, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it priced an underwritten public offering of 7,812,500 shares of its common stock at a price to the public of $96.00 per share.

Insmed Announces Pricing of $750 Million Public Offering of Common Stock

Insmed Announces Proposed $650 Million Public Offering of Common Stock

BRIDGEWATER, N.J. , June 11, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it intends to offer and sell $650 million of shares of its common stock in an underwritten public offering.

Insmed Announces Proposed $650 Million Public Offering of Common Stock

Insmed's Pulmonary Hypertension Drug Data Exceeded Even Bullish Outlook, Analysts Boost Price Forecast

Insmed Incorporated INSM on Tuesday released topline results from its Phase 2b study of treprostinil palmitil inhalation powder (TPIP), administered once daily in patients with pulmonary arterial hypertension.

Insmed's Pulmonary Hypertension Drug Data Exceeded Even Bullish Outlook, Analysts Boost Price Forecast

Zacks Investment Research

Insmed Stock Jumps 29% on Encouraging PAH Study Results

INSM eyes the next steps as TPIP hits all endpoints in the PAH study, setting the stage for late-stage trials and broader potential in lung disease.

Insmed Stock Jumps 29% on Encouraging PAH Study Results

CNBC Television

Insmed CEO Will Lewis on stock surge after positive trial results

Will Lewis, Insmed Chair & CEO, joins 'Fast Money' to talk its recent trial results for Pulmonary Arterial Hypertension therapy, the stock reaction, and more.

Insmed CEO Will Lewis on stock surge after positive trial results

Insmed: Company Presses On With Further POC PAH Treatment Data

Insmed achieved positive phase 2b results for TPIP in PAH, meeting all endpoints and paving the way for phase 3 trials in 2025-2026. The global pulmonary arterial hypertension market is expected to reach $12.2 billion by 2032. Brensocatib's NDA for bronchiectasis is under Priority Review, with a PDUFA date of August 12, 2025, targeting an untapped market.

Insmed: Company Presses On With Further POC PAH Treatment Data

Proactive Investors

Insmed shares surge on positive trial results for pulmonary arterial hypertension therapy

Insmed Incorporated (NASDAQ:INSM) shares surged more than 27% after the company unveiled positive results from a Phase 2b of its once-daily pulmonary arterial hypertension (PAH) therapy, treprostinil palmitil inhalation powder (TPIP). The randomized, double-blind, placebo-controlled study met its primary endpoint as well as all secondary efficacy endpoints.

Insmed shares surge on positive trial results for pulmonary arterial hypertension therapy

Investors Business Daily

Insmed Catapults Into Breakout Territory On A 'Home Run' For Its Rival To United, Liquidia

Insmed stock catapulted into breakout territory early Tuesday after the biotech company hit a "home run" with its treatment for PAH.

Insmed Catapults Into Breakout Territory On A 'Home Run' For Its Rival To United, Liquidia

Insmed's blood pressure drug meets main goal in mid-stage trial

Insmed said on Tuesday that its experimental blood pressure drug met the main goals in a mid-stage study.

Insmed's blood pressure drug meets main goal in mid-stage trial

Insmed Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once-Daily Therapy in Patients with Pulmonary Arterial Hypertension

–The Study Met Primary and All Secondary Efficacy Endpoints– Statistically Significant 35% Placebo-Adjusted Reduction from Baseline in Pulmonary Vascular Resistance for the Primary Endpoint (p

Insmed Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once-Daily Therapy in Patients with Pulmonary Arterial Hypertension

See News Rankings

Charts implemented using Lightweight Charts™